Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Gilead Sciences

Status and phase: Active, not recruiting; Phase 3

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer

Treatments: Drug: Paclitaxel; Drug: Capecitabine; Drug: Nab-paclitaxel; Drug: Sacituzumab Govitecan-hziy

Study type: Interventional

Funder types: Industry

Identifiers

NCT05840211

MOH_2023-07-17_012821 (Other Identifier)

jRCT2061230032 (Other Identifier)

CTR20233370 (Registry Identifier)

2022-502593-17-00 (Other Identifier)

GS-US-598-6168

DOH-27-082023-6901 (Other Identifier)

Details and patient eligibility

About

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).

Enrollment: 654 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Able to understand and give written informed consent.

• Must have adequate tumor tissue sample preferably from locally recurrent or metastatic site.

• Documented evidence of HR+ metastatic breast cancer (mBC) confirmed with the most recently available tumor biopsy preferably from a locally recurrent or metastatic site.

• Documented evidence of HER2- status.

• Documented PD by computed tomography (CT) or magnetic resonance imaging during or after the most recent therapy per RECIST v1.1 criteria.

• Candidate for the first chemotherapy in the locally advanced or metastatic setting.

• Eligible for capecitabine, nab-paclitaxel, or paclitaxel.

• Individuals must have at least one of the following:

  • Disease progression on at least 2 or more previous lines of endocrine therapy (ET) with or without a targeted therapy in the metastatic setting.

    • Disease recurrence while on the first 24 months of starting adjuvant ET will be considered a line of therapy; these individuals will only require 1 line of ET in the metastatic setting.

  • Disease progression within 6 months of starting first-line ET with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor (if ineligible or if unable to access a CDK 4/6 inhibitor) in the metastatic setting.

  • Disease recurrence while on the first 24 months of starting adjuvant ET with CDK 4/6 inhibitor and if the individual is no longer a candidate for additional ET in the metastatic setting.

• Individuals may have received prior targeted therapies, including but not limited to PARP inhibitors (for those with germline BRCA1 or BRCA2 mutations), phosphatidylinositol 3-kinase (PI3K) inhibitors (for those with PIK3CA mutations), or mammalian target of rapamycin (mTOR) inhibitors. However, individuals can no longer be candidates for additional endocrine treatment with or without targeted therapies.

• Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.

• Demonstrates adequate organ function.

• Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Key Exclusion Criteria:

• Progressive disease within 6 months of completing (neo)adjuvant chemotherapy.

• Locally advanced metastatic breast cancer (mBC) (Stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.

• Current enrollment in another clinical study and use of any investigational device or drug (drugs not marketed for any indication) either within 5 half-lives or 28 days prior to randomization, whichever is longer.

  • Use of investigational drugs in the category of Selective Estrogen Receptor Degraders are acceptable if last dose was longer than 14 days prior to randomization.

• Received any prior treatment (including antibody-drug conjugate (ADC)) containing a chemotherapeutic agent targeting topoisomerase I.

• Received any prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC.

• Have an active second malignancy.

• Have an active serious infection requiring antibiotics.

• Have active hepatitis B virus (HBV) or hepatitis C virus (HCV).

• Individuals positive for human immunodeficiency virus type 1/2 (HIV-1 or -2) with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.

• Have a positive serum pregnancy test or are breastfeeding for individuals who are assigned female at birth.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

654 participants in 2 patient groups

Sacituzumab Govitecan-hziy (SG)

Experimental group

Description:

Participants will receive SG at a dose of 10 mg/kg infusion on Days 1 and 8 of a 21-day cycle.

Treatment:

Drug: Sacituzumab Govitecan-hziy

Treatment of Physician's Choice (TPC)

Active Comparator group

Description:

Participants will receive TPC determined prior to randomization to 1 of the 3 allowed regimens: * paclitaxel 80 mg/m\^2 over 1 hour (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * nab-Paclitaxel 100 mg/m\^2 over 30 minutes (± 10 minutes) on Days 1, 8, and 15 of a 28-day cycle. * capecitabine at 1000-1250 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period of a 21-day cycle.

Treatment:

Drug: Nab-paclitaxel

Drug: Capecitabine

Drug: Paclitaxel